Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the prurigo nodularis treatment industry, and what growth rate is it expected to achieve?
The prurigo nodularis treatment market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing investment in dermatology research, rising demand for personalized medicine, growing pipeline of novel therapies, increasing regulatory approvals for treatment options, and rising use of teledermatology services.
The prurigo nodularis treatment market size is expected to see strong growth in the next few years. It will grow to $2.11 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rising healthcare expenditure, growing awareness of prurigo nodularis, growing demand for targeted therapies, rise in research and development activities, and increasing approvals of novel treatments. Major trends in the forecast period include advancement in biologic therapies, advanced diagnostic approaches for skin conditions, innovation in topical treatment formulations, integration of teledermatology services, and advanced patient-centric care models.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24390&type=smp
What are the major drivers contributing to the growth of the prurigo nodularis treatment market?
The rising incidence of chronic skin conditions is expected to propel the growth of the prurigo nodularis treatment market going forward. Chronic skin conditions refer to long-lasting or recurring skin disorders that often require ongoing management and can significantly affect a person’s quality of life. The increase in chronic skin conditions is rising due to greater exposure to environmental pollutants, which can damage the skin’s natural barrier and cause prolonged inflammation. Prurigo nodularis treatment addresses the root causes of chronic skin conditions by targeting the inflammatory pathways responsible for persistent itching and skin lesions. By regulating the immune system’s overactivity, these therapies effectively relieve symptoms and enhance the quality of life for those with chronic prurigo nodularis. For instance, in July 2023, according to the Office of Health Economics (OHE), a UK-based registered charity, hidradenitis suppurativa (HS), a painful chronic skin disease, affects at least 200,000 people in the UK, and the economic impact of hidradenitis suppurativa is estimated to be around £3.83 ($4.35) billion annually. Therefore, the rising incidence of chronic skin conditions is driving the growth of the prurigo nodularis treatment market.
What are the major market segments driving the growth of the prurigo nodularis treatment industry?
The prurigo nodularis treatment market covered in this report is segmented –
1) By Treatment: Medication, Cryotherapy, Phototherapy, Pulsed Dye Laser, Other Treatments
2) By Diagnosis: Skin Biopsy, Blood Tests, Other Diagnosis
3) By Route Of Administration: Topical Administration, Oral Administration, Parenteral Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-Users: Clinic, Hospital, Other End-Users
Subsegments:
1) By Medication: Topical Corticosteroids, Antihistamines, Immunosuppressants, Neuromodulators, Biologic Therapies
2) By Cryotherapy: Liquid Nitrogen Application, Spray-Freezing Techniques, Cryoprobe Therapy
3) By Phototherapy: Narrowband Ultraviolet B (NB-UVB), Broadband Ultraviolet B (BB-UVB), Psoralen Plus Ultraviolet A (PUVA)
4) By Pulsed Dye Laser: 585 Nanometer (nm) Wavelength Therapy, 595 Nanometer (nm) Wavelength Therapy
5) By Other Treatments: Behavioral Therapy, Acupuncture, Emollients and Moisturizers, Surgical Excision
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/prurigo-nodularis-treatment-global-market-report
What evolving trends are creating new opportunities in the prurigo nodularis treatment market?
Major companies operating in the prurigo nodularis treatment market are focused on developing advanced therapies, such as monoclonal antibodies, to target specific immune pathways and provide more effective relief from symptoms. Monoclonal antibodies are laboratory-made molecules designed to mimic the immune system’s ability to fight off harmful pathogens, such as viruses. For instance, in August 2024, Galderma, a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Nemluvio (nemolizumab) as a treatment for adult patients with prurigo nodularis. The approval was based on positive results from the OLYMPIA clinical trials, where Nemluvio demonstrated significant improvement in itch intensity and skin nodules. This treatment specifically targets IL-31 signaling, addressing a key factor driving prurigo nodularis symptoms.
Who are the key market players contributing to the growth of the prurigo nodularis treatment industry?
Major companies operating in the prurigo nodularis treatment market are Roche Holding AG, Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals Inc., Galderma S.A, Incyte Corporation, LEO Pharma A/S, Almirall S.A., Maruho Co. Ltd., VYNE Therapeutics Inc., Kiniksa Pharmaceuticals Ltd., Trevi Therapeutics Inc., Healio, Keymed Biosciences Inc., MyHealthTeam, Shanghai SIGMA High-tech Co. Ltd., Celgene Corporation, Dermatology Treatment and Research Center, Hightower Clinical, Celldex Therapeutics Inc., Psoriasis Treatment Center of Central New Jersey, Skin Care Research.
Which regions are leading the growth of the prurigo nodularis treatment market globally?
North America was the largest region in the prurigo nodularis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prurigo nodularis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Prurigo Nodularis Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24390&type=smp
Need Customized Data On Prurigo Nodularis Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24390&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
